Sartans Market Report 2026

Sartans Market Overview

• Sartans market size has reached to $22.18 billion in 2025 • Expected to grow to $27.14 billion in 2030 at a compound annual growth rate (CAGR) of 4.1% • Growth Driver: Rising Prevalence Of Hypertension Is Fuelling The Growth Of The Market Due To Increasing Incidence And Health Risks Associated With High Blood Pressure • Market Trend: Advancements In Tablet-Form Sartans For Enhanced Treatment Efficacy And Patient Adherence • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Sartans Market?

Sartans also known as angiotensin II receptor blockers (ARBs) are medications commonly prescribed to manage high blood pressure (hypertension) and heart failure. They block the action of angiotensin II, a hormone that causes blood vessels to constrict, by promoting relaxation of the vessels, lowering blood pressure, and improving circulation. Sartans help reduce the risk of strokes, kidney damage, and heart attacks in individuals with specific cardiovascular conditions. The main product types of sartans are valsartan, telmisartan, losartan, irbesartan, azilsartan and olmesartan. Valsartan is an angiotensin II receptor blocker (ARB), which lowers blood pressure and reduces heart strain by relaxing blood vessels. It is distributed through various distribution channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others for several applications including hypertension, cardiovascular diseases, kidney diseases, and others, and is used by various end-users such as hospitals, diagnostic laboratories, and others.

What Is The Sartans Market Growth Forecast?

The sartans market size is expected to see steady growth in the next few years. It will grow to $27.14 billion in 2030 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to aging population, rising kidney disease incidence, demand for cost-effective therapies, outpatient treatment expansion, growth of digital pharmacies. Major trends in the forecast period include increasing use in hypertension management, growth of generic angiotensin receptor blockers, preference for combination cardiovascular therapy, expansion of online pharmacy distribution, focus on renal and cardiovascular protection.

Global Sartans Market Segmentation

1) By Product Type: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels 3) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications 4) By End-User: Hospitals, Other End-Users Subsegments: 1) By Valsartan: Film-Coated Tablets, Oral Powder Sachets, Triple-Combination Tablets, Ready-To-Use Liquid Formulations 2) By Telmisartan: Soft Gel Capsules, Mouth-Dissolving Strips, Sustained-Release Tablets, Sachet-Packed Granules 3) By Losartan: Chewable Tablets, Pediatric Oral Drops, Effervescent Tablets, Dispersible Tablets 4) By Irbesartan: High-Potency Tablets, Scored Tablets, Hospital Bulk Packs, Blister Strip Packs 5) By Azilsartan: Nanoparticle-Based Tablets, Rapid-Onset Tablets, Unit-Dose Capsules, Microgranule Sachets 6) By Olmesartan: Oral Jelly Formulations, Oral Thin Films, Powder-For-Suspension Packs, Dual-Layer Tablets

What Is The Driver Of The Sartans Market?

The rising prevalence of hypertension is expected to propel the growth of the sartans market going forward. Hypertension is a condition marked by persistently high blood pressure, which can raise the likelihood of heart disease, stroke, and other severe health complications. The growing incidence of hypertension is linked to diets rich in salt and processed foods, which lead to fluid retention and increased heart strain. Sartans treat hypertension by blocking angiotensin II, a hormone that narrows blood vessels. It helps relax and widen the vessels, lowering blood pressure and easing the heart's workload. For instance, in September 2025, according to the World Health Organization, a Switzerland-based international public health agency, an estimated 1.4 billion adults aged 30–79 years worldwide were living with hypertension in 2024, representing about 33% of the global population. Therefore, the rising prevalence of hypertension is driving the growth of the sartans industry.

Key Players In The Global Sartans Market

Major companies operating in the sartans market are Viatris Inc., Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Apotex Inc., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Cadila Pharmaceuticals Ltd., Lupin Ltd., Zydus Lifesciences Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Unichem Laboratories Ltd., Emcure Pharmaceuticals Ltd., Mylan N.V., Hikma Pharmaceuticals PLC, Glenmark Pharmaceuticals Ltd., Abbott Laboratories, Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Bayer AG, Merck & Co. Inc.

Global Sartans Market Trends and Insights

Major companies operating in the sartans market are focusing on developing advanced products, such as tablet-form sartans, to enhance treatment efficacy and patient adherence. Tablet-form sartans are oral medications that include sartan drugs, which block the effects of angiotensin II, promoting the relaxation of blood vessels and reducing blood pressure. For instance, in July 2024, Zydus Lifesciences, an India-based pharmaceutical company, received the US Food and Drug Administration (FDA) approval for Valsartan Tablets USP (40 mg, 80 mg). These tablets are marketed under the brand name Diovan. These tablets are prescribed to treat hypertension and heart failure and to improve survival post-heart-attack in adults and are also suitable for pediatric patients aged one year and older.

What Are Latest Mergers And Acquisitions In The Sartans Market?

In April 2025, Scienture Holdings, Inc., a US-based manufacturer of sartans, partnered with Saptalis Pharmaceuticals to manufacture Arbli (losartan potassium oral suspension, 10 mg/mL). The collaboration includes warehousing and distribution agreements with strategic partners to ensure market readiness for the first FDA-approved ready-to-use oral liquid losartan, addressing unmet needs in hypertension treatment. Saptalis Pharmaceuticals is a US-based pharmaceutical company.

Regional Insights

North America was the largest region in the sartans market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Sartans Market?

The sartans market consists of sales of candesartan, eprosartan, and fimasartan. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Sartans Market Report 2026?

The sartans market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the sartans industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.